Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

61509 1497862462HCLSReviewTaiwanJune2017.pdf
Energy Boardroom

FDA CRDAC: Novartis' serelaxin not ready for prime time

28.03.2014 / Scripintelligence

The FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 11-0 in recommending against approval of serelaxin – putting much of the blame for serelaxin’s troubles on the confusing design of the single trial Novartis used to…

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: